Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings, LLC reports developments as a public venture platform and investment holding company focused on launching and supporting disruptive technology companies. Its news commonly covers shareholder updates, operating results, portfolio-company positions, capital-market services and the activity of subsidiaries that combine broker-dealer, intellectual property and technology-development functions.
Company updates also feature PatentVest, MDB’s intellectual property intelligence, strategy and legal-services business. Recurring PatentVest releases discuss IP landscape reports, patent strategy, legal insights, biotechnology and medical-technology collaborations, and equity-linked service engagements that connect patent research, due diligence and venture formation.
MDB Capital Holdings (NASDAQ: MDBH) announced board transitions effective February 1, 2026. Jeb Terry, Sr. was appointed to the board; Susanne L. Meline concluded her board service and will remain a shareholder and advocate. The company cited Terry's two decades in microcap life sciences investing and his leadership at Aberdeen Investment Management (2010–2025).
MDB said these changes support its strategy to scale a public venture platform that launches and finances early-stage, category-leading companies.
PatentVest (MDBH) released a PatentVest Pulse report on Jan 14, 2026 titled The Patent Battlefield, analyzing patent data across the $1.8 trillion space economy.
The study covers 1,450+ launch-related patent families and finds: SpaceX's IP points to Starlink as its core business rather than launch; Blue Origin is building early IP positions in cislunar markets; Rocket Lab relies heavily on acquired IP; and China and state-backed entities dominate global launch-related filings. The report frames these IP positions as indicators of IPO readiness, competitive risk, and likely value capture as the sector mainstreams.
MDB Capital Holdings (NASDAQ: MDBH) provided an operational update for the quarter ended September 30, 2025 and subsequent developments on November 20, 2025. Key items include an anticipated close this week of a $16.8 million private placement for Paulex Bio and a planned $20 million IPO for Buda Juice in December 2025. Management said the company expanded its pipeline of early-stage, category-disrupting companies, improved platform efficiency, and broadened investor relationships, including TCA Venture Group, Keiretsu Forum MST, and RIAs.
Management will host a Zoom webinar today at 4:30 p.m. ET led by CEO Christopher Marlett to review developments and answer questions; the live webcast is available via MDB investor relations.
MDB Capital Holdings (NASDAQ: MDBH) will host a third quarter 2025 business update via Zoom webinar on Thursday, November 20, 2025 at 4:30 p.m. ET. A press release with results will be issued prior to the call. Christopher Marlett, CEO and co-founder, will lead the presentation and may be joined by other management to review developments, ongoing initiatives and anticipated milestones, followed by a question-and-answer period. Investors can pre-register for the Zoom webinar or access the live webcast on the day of the event via the company investor relations site at https://investors.mdb.com/.
PatentVest (MDBH) released a PatentVest Pulse report on Oct. 28, 2025 titled “The State of Cardiac Technology: The Path to Total Cardiac Intelligence.” The report sizes the opportunity as a $133 billion global cardiac diagnostics market and maps IP driving the shift from hospital-bound 12-lead ECGs to portable, connected systems.
Key facts: PatentVest captured 581 patent families across 243 organizations. The report highlights consumer wearables (Apple, Samsung, Google/Fitbit, Whoop, Oura, Withings, Garmin, Zepp Health, Masimo) focused on single-lead ECGs, and names innovators (HeartBeam, iRhythm, AliveCor, Mayo Clinic, Tempus AI, Eko Health, Anumana, Medical AI Co., Bodyfriend Co.). HeartBeam is cited as the first to a cable-free 12-lead ECG replication.
MDB Capital Holdings (NASDAQ: MDBH) will present at LD Micro Main Event XIX on Tuesday, October 21, 2025 at 10:30 AM PT at the Hotel del Coronado in San Diego and via virtual webcast.
Chris Marlett, CEO and co‑founder, will give the presentation. MDB noted it is the 2,000th company to present at LD Micro and said this is the firm's first presentation at a microcap conference. LD Micro Main Event XIX runs October 19–21, 2025, features ~120 companies, half‑hour presentation slots, and investor one‑on‑one meetings and receptions.
LD Micro (a subsidiary of Freedom US Markets) announced that MDB Capital Holdings (NASDAQ: MDBH) is the 2,000th company to present on its platform, according to the press release dated October 6, 2025.
The PR states LD Micro was founded in March 2006 and notes the decline in U.S. public companies from about 8,000 to ~4,000 over two decades. MDB Capital will present at the LD Micro Main Event on Tuesday, October 21, 2025 at 10:30 am, marking MDB's first microcap conference presentation.
PatentVest, a division of MDB Capital Holdings (NASDAQ: MDBH), has announced the appointment of Dr. Sarah Cork as Senior Patent Attorney. Dr. Cork brings over a decade of experience in biotechnology, pharmaceutical, and medical device intellectual property matters, complemented by a Ph.D. in Neuroscience.
Dr. Cork specializes in complex IP matters including recombinant technology, biologics, immunotherapies, gene therapy, and AI-enabled precision medicine. Her expertise spans patent litigation, prosecution, IP due diligence, and freedom-to-operate analyses, with significant experience in BPCIA cases and Hatch-Waxman matters.
Beyond her legal practice, Dr. Cork serves as President of the Los Angeles Intellectual Property Law Association and is active in the Pasadena Angels investor group and SBIR grant review process.
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform, has provided its Q2 2025 operational update highlighting several key developments. The company announced a private offering for Paulex Bio, which is developing an oral diabetes medication, and filed an S-1 for Buda Juice's IPO.
Notable developments include a strategic partnership with Keiretsu Forum MST for the IPO Angels platform and plans to spin out PatentVest as an independent public company in 2026. MDB is strengthening its position in public markets while expanding relationships with RIAs to reach investors seeking venture exposure.
PatentVest and Docana (MDBH) have announced a strategic partnership focused on integrating IP strategy and AI innovation. Under the agreement, PatentVest will provide strategic legal and IP consulting services to protect Docana's technology portfolio, while gaining access to Docana's next-generation AI platform.
The partnership aims to enhance both companies' capabilities: PatentVest will help Docana develop comprehensive IP protection strategies, while Docana's AI platform will optimize PatentVest's internal knowledge workflows. This collaboration demonstrates how AI technology can transform IP strategy services while ensuring proper protection for AI innovations.